Stille (STIL) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
13 Jun, 2025Executive summary
Net sales in Q3 2024 reached MSEK 127.9, up 82.4% year-over-year, with 7.4% organic growth and significant contribution from the Fehling acquisition.
Gross margin improved to 51.8% from 46.7% due to operational improvements and favorable geographic mix.
Operating profit before non-recurring items rose to MSEK 23.4 (11.9), with an operating margin of 18.3%.
Cash flow from operating activities increased to MSEK 15.2 (7.3), and cash and cash equivalents at period end were MSEK 97.9 (41.2).
The integration of Fehling is proceeding as planned, supporting growth and product portfolio alignment.
Financial highlights
Q3 EBITDA before non-recurring items was MSEK 30.2 (15.5), EBITDA margin 23.6% (22.1%).
Profit after tax for Q3 was MSEK 12.7 (9.7); EPS SEK 1.41 (1.93).
For Jan–Sep, net sales were MSEK 410.2 (217.6), gross margin 49.8% (44.6%), and operating profit before non-recurring items MSEK 79.4 (34.3).
Net debt/LTM EBITDA before non-recurring items at 0.2, equity/assets ratio 65.4% (56.4%).
Outlook and guidance
Revised financial targets: organic growth >10%, EBITDA margin before non-recurring items >25%, net debt/LTM EBITDA <3.
Management remains confident in continued organic and acquisition-driven growth, with a strong platform for future value-adding acquisitions.
Latest events from Stille
- Q4 sales up 8.5% with strong surgical tables demand; outlook for 2026 remains positive.STIL
Q4 202512 Feb 2026 - Sales rose 8.5% in Q3, but margins fell; supply chain and growth outlook improve for 2026.STIL
Q3 202523 Oct 2025 - Sales declined 12.6% but margin and order intake improved; UK acquisition to boost growth.STIL
Q2 202517 Jul 2025 - Net sales nearly doubled in Q2 2024, fueled by Fehling's acquisition and robust organic growth.STIL
Q2 202413 Jun 2025 - Despite lower sales, improved margins and strong order intake support a positive outlook.STIL
Q1 20256 Jun 2025 - Stille AB doubled sales and improved profitability in 2024, focusing on premium surgical solutions.STIL
Q4 20245 Jun 2025